Advertisement
News
Advertisement

Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors

Fri, 04/19/2013 - 11:17am

Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, protein biomarker-based assay for appendicitis, today announced the appointment of Stephen A. Williams, M.D., Ph.D., Chief Medical Officer at SomaLogic, to the Company's Board of Directors.  Dr. Williams brings his experience in diagnostic imaging and biomarker discovery to the Venaxis Board.

Steve Lundy, President and CEO of Venaxis, stated, "We are happy to welcome Steve to our Board and look forward to the benefit of his deep experience, both in diagnostic imaging, which is relevant to our market development and commercial strategy for the APPY1 Test, as well as in clinical biomarker validation, which will be instrumental to us in our evaluation and development of future Venaxis products." Dr. Williams stated, "The APPY1 Test is an excellent example of how characterization of clinically relevant biomarkers can produce useful tools for addressing important diagnostic challenges.  With the potential to reduce the safety risks associated with current diagnostic imaging techniques in the emergency setting, I believe there is significant clinical need and utility for the APPY1 Test.  I am excited to join the Venaxis Board and to support the further development and commercialization of this, as well as potential future, biomarker-based diagnostic products." Dr. Williams joined SomaLogic in 2009 as Chief Medical Officer.  Prior to his time at SomaLogic, Dr. Williams trained as a physician at Charing Cross and Westminster Medical School, University of London, and following his internships, returned to the same institution for a Ph.D. in medicine and physiology.  He subsequently performed three years of residency in diagnostic imaging at the University of Newcastle upon Tyne.  In 1989 he joined Pfizer U.K. in experimental medicine and worked on a variety of programs including asthma, irritable bowel syndrome, migraine [eletriptan], depression [sertraline] and urinary incontinence [darifenacin].  He moved to the U.S. in 1993 with Pfizer and worked on programs in inflammatory bowel disease, stroke, psychosis [ziprasidone] and head injury.  He created the clinical technology group in 1997, which became a worldwide function on five research sites with the objective of validating clinical biomarkers and measurements, and was named vice president in 2006.  Dr. Williams served on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering from 2004-2007 and the executive Committee of the Biomarkers Consortium run by the Foundation for NIH from 2005-2007.  In process initiatives, he led or co-led initiatives in diagnostics, biomarkers, quality of drug candidates, and guidelines for development teams to make the decision to start Phase 3 trials.

 

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading